Topics

Managing partner at Numerof & Associates.

Articles

How can buyers maximize the value of their acquisitions?

Key Elements for Success in Pharma M&A Integration

Videos

In a final part of his interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, explains the amount of time it takes to see a reduction in annualized drug spend, and offers estimates in terms of percent savings. 

The Financial Benefits of Technology

In an interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, discusses why mitigating the impact of rising costs is imperative, while explaining the benefit of advanced analytics tools.

Streamlining Pharmacy Purchasing and Procurement 

The company boosts its healthcare logistics services by agreeing to purchase Frigo-Trans and its sister company BPL.

UPS Makes Cold-Chain Strides Via New Acquisitions

The joint venture aims to disrupt pathological lncRNA interactions with RNA-binding proteins using NextRNA’s platform.

Bayer, NextRNA Therapeutics Agree to Strategic Collaboration to Develop Small Molecule Therapeutics

Partnership adds supply chain efficiencies, while prioritizing patient safety. 

Intelliguard, Cencora Collaborate on Boosting RFID-Tagged Medication Compatibility

The partnership creates an integrated solution that also tackles compliance challenges within the sector. 

LSPedia, Pharma Logistics Strike Up Supply Chain Visibility Collaboration

A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.

An Examination of Big Pharma Inventories

The collaboration—which is now active until 2031, features a $25 million payment to Evotec for progress made in neurodegenerative disease research.

Evotec-Bristol Myers Squibb Partnership Further Develops as Pipeline Expands

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Business and Finance